Urinary Tract Infection Treatment Market Set for Rapid Growth and Trend

Posted by Pooja Mahajan on November 22nd, 2019

Urinary Tract Infection Treatment Market: Introduction

Transparency Market Research has published a new report on the global urinary tract infection treatment market. According to the report, the global urinary tract infection treatment market was valued at ~US$ 5.9 Bn in 2018, and is projected to expand at a CAGR of ~3% from 2019 to 2027.

Urinary tract infection (UTI) is a common infection caused due to the presence of a pathogen. E. coli is a common uropathogen that causes UTI. Antibiotics such as ciprofloxacin, cephalosporins, and penicillin are used for the treatment of urinary tract infection. Diagnostic tests and assays play a vital role in the screening and diagnosis of urinary tract infection.

Urinary Tract Infection Treatment Market: Segment Analysis

In terms of disease, the complicated UTI segment held a major share of the global urinary tract infection treatment market in 2018. The segment is anticipated to dominate the global urinary tract infection treatment market during the forecast period, attributed to a decrease in the efficacy of therapies and increase in incidences of pathogen colonization. The segment is expected to grow at a rapid pace during the forecast period.

Get Sample with Latest Research @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=72872

Based on drug class, the quinolones segment accounted for a major share of the urinary tract infection treatment market in 2018. The segment is likely to grow at a rapid pace during the forecast period. Rise in the number of physicians prescribing quinolones for the treatment of urinary tract infection is projected to drive the segment. Moreover, the introduction of new antibiotics due to microbial resistance is anticipated to fuel the growth of the segment.

In terms of pathogen, the E. coli segment held a major share of the urinary tract infection treatment market in 2018. The segment is expected to grow at a rapid pace during the forecast period. Increase in geriatric patients with urinary tract infection is likely boost the growth of the segment.

According to the World Health Organization, community-acquired UTI is most commonly caused due to E. coli. Based on source of infection, the hospital-acquired UTI segment accounted for a major market share in 2018. The segment is projected grow at a rapid pace during the forecast period due to an increase in the use of catheters during hospital stay. An article published in Skin Diseases and Skin Care stated that, 40% of urinary tract infections are hospital-acquired infections.

In terms of gender, the female segment is anticipated to grow at a rapid pace during the forecast period. An article published in NCBI indicated that, the prevalence of UTI in women ranges from 0.5 to 0.7 per person-years.

Based on distribution channel, the hospital pharmacies segment held a major share of the UTI treatment market in 2018.

Global Urinary Tract Infection Treatment Market: Prominent Regions

North America held a major share of the global urinary tract infection treatment market in 2018. The urinary tract infection treatment market in the region is estimated to expand at a moderate CAGR from 2019 to 2027. The urinary tract infection treatment market in North America is primarily driven by the growth strategies adopted by key players and early adoption of advanced techniques for the diagnosis of urinary tract infection. For instance, in July 2018, Nabriva Therapeutics plc acquired Zavante Therapeutics. This acquisition enabled the company to strengthen its position in the anti-infectives market. In July 2018, Lupin received the U.S. Food and Drug Administration approval for the generic Nitrofurantoin capsule. It is used for the treatment of urinary tract infection caused due to enterococci, staphylococcus aureusm, klebsiella, and E. coli.

Asia Pacific accounted for a significant share of the global urinary tract infection treatment market in 2018. The urinary tract infection treatment market in the region is expected to grow at a rapid pace during the forecast period. Increase in the number of people with UTI and rise in awareness are likely fuel the growth of the market in the region. In March 2018, an awareness session on urinary tract infection in women was arranged in India.

Europe too held significant share of the global urinary tract infection treatment market in 2018. Rise in the prevalence of urinary tract infection is projected to drive the urinary tract infection treatment market in the region. According to the National Institute for Health and Care Excellence, an estimated 224,670 admissions were recorded for UTI in the U.K alone.

Global Urinary Tract Infection Treatment Market: Competition

The global urinary tract infection treatment market is moderately fragmented, with the top three to four players accounting for 40% to 50% market share. Key manufacturers engage in new product launches & approvals, collaborations, acquisitions, and distribution agreements.

In January 2017, Allergan received the U.S. FDA approval to update the label of AVYCAZ for the treatment of pyelonephritis and complicated urinary tract infection. In June 2018, GlaxoSmithKline plc identified orally available small molecule development for the treatment and prevention of urinary tract infection, under a joint research collaboration with Fimbrion Therapeutics, Inc. In July 2018, Lupin received the U.S. Food and Drug Administration approval for generic Nitrofurantoin capsule. It is used for the treatment of urinary tract infection caused due to enterococci, staphylococcus aureusm, klebsiella, and E. coli. In August 2014, Allergan acquired the TARIS Biomedical LiRIS program to strengthen its position in the urology market, and to accelerate the development of innovative treatments.

Leading players operating in the global urinary tract infection treatment market are Allergan, Bayer AG, Pfizer, Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, Janssen Global Services, LLC, Lupin Ltd., Merck & Co., Inc. (Merck Sharp & Dohme Corp), Dr. Reddy’s Laboratories Ltd., and Almirall, S.A.